Exhibiting at VIV Asia 2025

Established in 1946, Nisseiken Co., Ltd. is a premier Japanese manufacturer specializing in veterinary vaccines and diagnostic agents. Headquartered in Ome City, Tokyo, Japan, the company plays a critical role in safeguarding the health of livestock through innovative biological products. With over seven decades of experience in veterinary pharmaceutical development, Nisseiken is widely regarded as a pioneer in Japan’s animal health industry.

Core Business

Nisseiken's operations focus on the research, development, manufacturing, and distribution of veterinary vaccines and diagnostic agents. The company has earned a reputation for producing high-efficacy vaccines across multiple animal categories, particularly for poultry, swine, horses, and cattle.

Their key business verticals include:

• Poultry Vaccines: Including live and inactivated vaccines such as Newcastle Disease (ND), Infectious Bursal Disease (IBD), and Infectious Bronchitis (IB) vaccines.
• Swine Vaccines: Notably the Porcine Reproductive and Respiratory Syndrome (PRRS) inactivated vaccine, as well as vaccines targeting Classical Swine Fever (CSF) and Porcine Parvovirus.
• Equine Vaccines: Their Equine Influenza Vaccine is widely adopted in Japan and recognized by the Japanese Racing Association.
• Cattle Vaccines: Vaccines designed for bovine respiratory diseases and other infectious threats.
• Diagnostic Agents: A comprehensive lineup of reagents used for disease monitoring and control programs in livestock.

Specialization and USP

Nisseiken's USP lies in its research-intensive operations, producing advanced biologicals specifically tailored to the epidemiological profile of diseases in Japan and Asia. The company operates one of Japan's few integrated vaccine development platforms that includes:

• Master seed strain development
• In-house animal testing
• Sterile production facilities
• Custom manufacturing

They also provide customized diagnostic kits and work closely with veterinary institutions and government animal health departments, contributing to national disease control strategies.

Financials and Market Standing

While Nisseiken Co., Ltd. is a privately held entity and does not publish its financial statements publicly, industry sources such as Teikoku Databank and Tokyo Shoko Research classify the company as a mid-sized pharmaceutical enterprise with annual revenues estimated between USD 30–70 million. This estimate is supported by their national market share in equine and poultry vaccines, along with long-term supply contracts with governmental veterinary bodies.

Shipment and Export Performance

Although the company primarily serves the domestic Japanese market, Nisseiken has been involved in selective international exports, particularly in Asia:

• According to ImportYeti and export data platforms, Nisseiken has shipped to countries such as Vietnam, Philippines, and Indonesia, mainly supplying poultry and swine vaccines.
• Recorded over 50 international shipments between 2020–2023, mostly under bilateral health cooperation programs.
• Their products are approved for use in regulated markets under Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF).

Target Market

Nisseiken primarily serves:

• Veterinary hospitals and clinics
• Livestock farms
• Racing horse institutions and breeders
• Government veterinary health departments
• University research institutions

They maintain partnerships with major veterinary pharmaceutical distributors across Japan and Southeast Asia.

Capabilities

The company boasts:

• GMP-certified manufacturing facilities
• High-biosecurity production zones for virus culture and vaccine development
• State-of-the-art biosafety level 3 (BSL-3) labs
• Nationally approved quality control systems for biologicals
• Ongoing collaborations with Japan’s National Institute of Animal Health

Certifications and Compliance

• GMP (Good Manufacturing Practice) certified by Japan’s Ministry of Agriculture, Forestry and Fisheries
• Biologics License Holder for all major veterinary vaccines in Japan
• Regular compliance audits and full traceability systems for all products
• Compliant with OIE (World Organisation for Animal Health) guidance on animal health products

Major Achievements

• Sole supplier of Equine Influenza Vaccine approved for use by the Japan Racing Association
• Contributor to the development of national diagnostic reagents for Classical Swine Fever (CSF)
• Over 75 years of uninterrupted veterinary pharmaceutical production
• Recognized contributor to national disease control programs including avian influenza surveillance and PRRS eradication

Nisseiken Co., Ltd. continues to lead Japan’s veterinary biologicals sector with a strong legacy, unmatched technical expertise, and a commitment to animal health through science-driven innovation.